Cited by 1,635Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesFerroptosis and cancer prognosis

The DOI matches its Crossref record; 70 of the 76 references it cites were found in a registry or an index.

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Open access

Gibney, Geoffrey T, Weiner, Louis M, Atkins, Michael B·2016·The Lancet Oncology

DOI 10.1016/s1470-2045(16)30406-5PMC PMC5702534

Open this paper in CoChat — free account

Abstract

The clinical development of checkpoint inhibitor-based immunotherapy has ushered in an exciting era of anticancer therapy. Durable responses can be seen in patients with melanoma and other malignancies. Although monotherapy with PD-1 or PD-L1 agents are typically well tolerated, the risk of immune-related adverse events increases with combination regimens. The development of predictive biomarkers is needed to optimise patient benefit, minimise risk of toxicities, and guide combination approaches. The greatest focus has been on tumour-cell PD-L1 expression. Although PD-L1 positivity enriches for populations with clinical benefit, PD-L1 testing alone is insufficient for patient selection in most malignancies. In this Review, we discuss the status of PD-L1 testing and explore emerging data on new biomarker strategies with tumour-infiltrating lymphocytes, mutational burden, immune gene signatures, and multiplex immunohistochemistry. Future development of an effective predictive biomarker for checkpoint inhibitor-based immunotherapy will integrate multiple approaches for optimal characterisation of the immune tumour microenvironment.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(16)30406-5

Cites

70 of 70 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citation
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802

Show all 76 references

Sorted by citations

Items 801–900 of 1,002

FHITlow / pHER2high signature in non‐small cell lung cancer is predictive of anti‐HER2 molecule efficacy
silva, J. D., Jouida, A., Ancel, J., Dalstein, V., Routhier, J., Delépine, G., Cutrona, J., Jonquet, A., Dewolf, M., Birembaut, P. L., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5439 · Cited by 16
Study protocol for an open-label, single-arm, phase Ib/II study of combination of toripalimab, nab-paclitaxel, and gemcitabine as the first-line treatment for patients with unresectable pancreatic ductal adenocarcinoma
Shui, L., Cheng, K., Li, X., Shui, P., Zhou, X., Li, J., Cheng, Y., & Cao, D. (2020) · BMC Cancer · doi:10.1186/s12885-020-07126-3 · Cited by 15
Therapeutic Status and Available Strategies in Pancreatic Ductal Adenocarcinoma
Thakur, G., Kumar, R., Kim, S.-B., Lee, S.-Y., Lee, S., & Rho, G. (2021) · Biomedicines · doi:10.3390/biomedicines9020178 · Cited by 16
Immune Checkpoint Molecules Expressed on CD4+ T Cell Subsets in Chronic Asymptomatic Hepatitis B Virus Carriers With Hepatitis B e Antigen-Negative
Cui, D., Jiang, D., Yan, C., Liu, X., Lv, Y., Xie, J., & Chen, Y. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.887408 · Cited by 16
Galectin-3 Decreases 4-1BBL Bioactivity by Crosslinking Soluble and Membrane Expressed 4-1BB
Nielsen, M. A., Juul‐Madsen, K., Stegmayr, J., Gao, C., Mehta, A. Y., Greisen, S. R., Kragstrup, T. W., Hvid, M., Vorup‐Jensen, T., Cummings, R. D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.915890 · Cited by 16
Patients deriving long-term benefit from immune checkpoint inhibitors demonstrate conserved patterns of site-specific mutations
Principe, D. R. (2022) · Scientific Reports · doi:10.1038/s41598-022-15714-5 · Cited by 17
Autophagy blockade potentiates cancer‐associated immunosuppression through programmed death ligand‐1 upregulation in bladder cancer
Tsai, T., Chang, A., Chen, P., Ho, C., Chen, H.-E., Chou, K., & Hwang, T. I. (2022) · Journal of Cellular Physiology · doi:10.1002/jcp.30817 · Cited by 18
Challenges and strategies for successful clinical development of immune checkpoint inhibitors in glioblastoma
Majd, N., & de Groot, J. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1621840 · Cited by 16
The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment—Review
Seliger, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02043 · Cited by 17
The Link Between Calcitriol and Anticancer Immunotherapy: Vitamin D as the Possible Balance Between Inflammation and Autoimmunity in the Immune-Checkpoint Blockade
Bersanelli, M., Leonetti, A., & Buti, S. (2017) · Immunotherapy · doi:10.2217/imt-2017-0127 · Cited by 16
Dynamics of peripheral blood inflammatory index predict tumor pathological response and survival among patients with locally advanced non-small cell lung cancer who underwent neoadjuvant immunochemotherapy: a multi-cohort retrospective study
Zhai, W., Zhang, C., Duan, F., Xie, J., Dai, S., Lin, Y., Yan, Q., Rao, B.-Y., Li, L., Zhou, Y., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1422717 · Cited by 16
Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma
Wang, B., Saddawi‐Konefka, R., Clubb, L. M., Tang, S., Wu, D., Mukherjee, S., Sahni, S., Dhruba, S. R., Yang, X., Patiyal, S., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-63538-4 · Cited by 16
Development and validation of a novel immune-related prognostic model in lung squamous cell carcinoma
Liu, Z., Wan, Y., Qiu, Y., Qi, X., Yang, M., Huang, J., & Zhang, Q. (2020) · International Journal of Medical Sciences · doi:10.7150/ijms.47301 · Cited by 15
Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective
Shi, W., & Zhao, W. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001090 · Cited by 15
Exploration of the Associations of lncRNA Expression Patterns with Tumor Mutation Burden and Prognosis in Colon Cancer
Ding, C., Shan, Z., Li, M., Xia, Y., & Jin, Z. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s300095 · Cited by 15
Dynamic peripheral blood immune cell markers for predicting the response of patients with metastatic cancer to immune checkpoint inhibitors
Chen, W., Wang, M., Gao, Q., Yuan, S., Deng, W., Bie, L., Ma, Y., Zhang, C., Li, S., Luo, S., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03221-5 · Cited by 15
Co-Targeting Luminal B Breast Cancer with S-Adenosylmethionine and Immune Checkpoint Inhibitor Reduces Primary Tumor Growth and Progression, and Metastasis to Lungs and Bone
Mehdi, A., Attias, M., Arakelian, A., Piccirillo, C. A., Szyf, M., & Rabbani, S. A. (2022) · Cancers · doi:10.3390/cancers15010048 · Cited by 15
Comprehensive Analyses Reveal Effects on Tumor Immune Infiltration and Immunotherapy Response of APOBEC Mutagenesis and Its Molecular Mechanisms in Esophageal Squamous Cell Carcinoma
Yang, J., Xiang, T., Zhu, S., Lao, Y., Wang, Y., Liu, T., Li, K., Ma, Y., Zhong, C., Zhang, S., et al. (2023) · International Journal of Biological Sciences · doi:10.7150/ijbs.83824 · Cited by 16
Reanalysis of single-cell data reveals macrophage subsets associated with the immunotherapy response and prognosis of patients with endometrial cancer
Wu, Q., Jiang, G., Sun, Y., & Li, B. (2023) · Experimental Cell Research · doi:10.1016/j.yexcr.2023.113736 · Cited by 15
GPR37 expression as a prognostic marker in gliomas: a bioinformatics-based analysis
Liang, K., Guo, Z., Zhang, S., Chen, D., Zou, R., Weng, Y., Peng, C., Xu, Z., Zhang, J., Liu, X., et al. (2023) · Aging · doi:10.18632/aging.205063 · Cited by 16
TCCIA: a comprehensive resource for exploring CircRNA in cancer immunotherapy
Wang, S., Xiong, Y., Zhang, Y., Wang, H., Chen, M., Li, J., Luo, P., Luo, Y., Hecht, M., Frey, B., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008040 · Cited by 15
Measuring the composition of the tumor microenvironment with transcriptome analysis: past, present and future
Zhang, H., Lu, X., Lu, B., Gullo, G., & Chen, L. (2024) · Future Oncology · doi:10.2217/fon-2023-0658 · Cited by 16
The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis
Ohara, K., Rendeiro, A. F., Bhinder, B., Eng, K., Ravichandran, H., Nguyen, D., Pisapia, D. J., Vosoughi, A., Fernandez, E. M., Shohdy, K. S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46320-w · Cited by 18
The Role of Aging and Senescence in Immune Checkpoint Inhibitor Response and Toxicity
Jain, S. S., Sojo, G. B., Sun, H., Friedland, B. N., McNamara, M. E., Schmidt, M. O., & Wellstein, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137013 · Cited by 17
A Wireless, Multicolor Fluorescence Image Sensor Implant for Real-Time Monitoring in Cancer Therapy
Roschelle, M., Rabbani, R., Gweon, S., Kumar, R., Vercruysse, A., Cho, N. W., Spitzer, M. H., Niknejad, A. M., Stojanovic, V. M., & Anwar, M. (2024) · IEEE Journal of Solid-State Circuits · doi:10.1109/jssc.2024.3435736 · Cited by 15
Alternative Strategies for Delivering Immunotherapeutics Targeting the PD-1/PD-L1 Immune Checkpoint in Cancer
Hoshi, R., Gorospe, K. A., Labouta, H. I., Azad, T., Lee, W. L., & Thu, K. L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16091181 · Cited by 16
Significance of Tumor Microenvironment Scoring and Immune Biomarkers in Patient Stratification and Cancer Outcomes
Alsibai, K. D., & Meseure, D. (2018) · InTech eBooks · doi:10.5772/intechopen.72648 · Cited by 18
Programmed Death Ligand 1 (PD-L1) Status and Tumor-Infiltrating Lymphocytes in Hot Spots of Primary and Liver Metastases in Prostate Cancer With Neuroendocrine Differentiation
von Hardenberg, J., Hartmann, S. E., Nitschke, K., Worst, T. S., Ting, S. C., Reis, H., Nuhn, P., Weis, C., & Erben, P. (2018) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2018.12.007 · Cited by 15
Highly multiplexed profiling of cell surface proteins on single circulating tumor cells based on antibody and cellular barcoding
Wang, C., Liu, Y., Wang, Z., He, J., & Shi, Q. (2019) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-019-01666-9 · Cited by 15
Integrin α2β1 Represents a Prognostic and Predictive Biomarker in Primary Ovarian Cancer
Dötzer, K., Schlüter, F., von Koch, F. E., Brambs, C., Anthuber, S., Frangini, S., Czogalla, B., Burges, A., Werner, J., Mahner, S., et al. (2021) · Biomedicines · doi:10.3390/biomedicines9030289 · Cited by 15
Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations
Izumi, M., Sawa, K., Oyanagi, J., Noura, I., Fukui, M., Ogawa, K., Matsumoto, Y., Tani, Y., Suzumura, T., Watanabe, T., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101102 · Cited by 15
Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC
Zhang, Z., Gu, Y., Su, X., Bai, J., Guan, W., Ma, J., Luo, J., He, J., Zhang, B., Geng, M., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.659321 · Cited by 15
The Heterogeneity of Infiltrating Macrophages in Metastatic Osteosarcoma and Its Correlation with Immunotherapy
Wang, Z., Wu, H., Chen, Y., Chen, H., Yuan, W., & Wang, X. (2021) · Journal of Oncology · doi:10.1155/2021/4836292 · Cited by 15
The viral expression and immune status in human cancers and insights into novel biomarkers of immunotherapy
Chen, S., Lai, H., Zhao, J., Chen, B., Li, Y., Li, Y., Li, Q., Zheng, Q., Huang, S., & Zhu, X. (2021) · BMC Cancer · doi:10.1186/s12885-021-08871-9 · Cited by 15
Analysis of the tumor microenvironment and mutation burden identifies prognostic features in thymic epithelial tumors.
Hou, X., Lin, S., Liu, Y., Wang, K., Yu, Z., Jia, J., Yu, J., Zheng, W., Bai, J., Chang, L., et al. (2022) · PubMed Central · Cited by 15
Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers part 2: Neuroendocrine tumours, hepatocellular carcinoma, and gastro-intestinal stromal tumours
Neuzillet, C., de Mestier, L., Rousseau, B., Mir, O., Hebbar, M., Kocher, H. M., Ruszniewski, P. B., & Tournigand, C. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.07.006 · Cited by 15
Epithelial-to-mesenchymal transition and its association with PD-L1 and CD8 in thyroid cancer
Aghajani, M. J., Yang, T., Schmitz, U., James, A. C., McCafferty, C. E., SOUZA, P. D., Niles, N., & Roberts, T. L. (2020) · Endocrine Connections · doi:10.1530/ec-20-0268 · Cited by 16
2D borophene nanostructures: Recent advances in synthesis, characterization, and emerging applications
Batool, M., Rather, J. A., Malik, A. H., Khanday, W. A., Wani, W. A., Wani, A. H., Bhaskar, R., & Kannan, P. (2025) · Surfaces and Interfaces · doi:10.1016/j.surfin.2025.106296 · Cited by 14
Improvement of the Anticancer Efficacy of PD‐1/PD‐L1 Blockade: Advances in Molecular Mechanisms and Therapeutic Strategies
Gao, P., Li, X., Duan, Z., Wang, Y., Li, Y., Wang, J., Luo, K., & Chen, J. (2025) · MedComm · doi:10.1002/mco2.70274 · Cited by 16
Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer
Kim, H.-S., Kim, R., Jo, H., Kim, H. R., Hong, J.-H., Ha, S. Y., Park, J. O., & Kim, S. T. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221117638 · Cited by 14
Advances in the application of immune checkpoint inhibitors in gynecological tumors
Zou, Y., Xu, Y., Chen, X., & Zheng, L. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109774 · Cited by 14
The Role of Immunotherapy in Esophageal and Gastric Cancer
Dedecker, H., Teuwen, L.-A. M. N., Vandamme, T., Domen, A., & Prenen, H. (2023) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2023.03.001 · Cited by 14
Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors
Stukalin, I., Navani, V., Gupta, M., Ruan, Y., Boyne, D. J., O'Sullivan, D. E., Meyers, D. E., Goutam, S., Sander, M., Ewanchuk, B. W., et al. (2023) · The Oncologist · doi:10.1093/oncolo/oyad073 · Cited by 14
Cancer Biology and Therapeutics: Navigating Recent Advances and Charting Future Directions
Cleanclay, W. D., Zakari, S., Adigun, T. O., Ayeni, T. O., Nnaji, P. C., Amuji, D. N., Blessing, A., Adebosoye, A., Gbadebo, M., Agbetuyi-Tayo, P., et al. (2023) · Tropical Journal of Natural Product Research · doi:10.26538/tjnpr/v7i12.4 · Cited by 17
Pan-cancer analysis reveals PDK family as potential indicators related to prognosis and immune infiltration
Tao, S., Tao, K., & Cai, X. (2024) · Scientific Reports · doi:10.1038/s41598-024-55455-1 · Cited by 14
Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors
Pan, M., Alavi, M., & Herrinton, L. J. (2018) · The Permanente Journal · doi:10.7812/tpp/17-149 · Cited by 15
Checkpoint inhibition in advanced gastroesophageal cancer: clinical trial data, molecular subtyping, predictive biomarkers, and the potential of combination therapies
Chuang, J., Chao, J., Hendifar, A. E., Klempner, S. J., & Gong, J. (2019) · Translational Gastroenterology and Hepatology · doi:10.21037/tgh.2019.08.04 · Cited by 14
Prognostic value of tumor-infiltrating lymphocytes (TILs) and their association with PD-L1 expression and DNA repair protein RAD51 in patients with resected non-small cell lung carcinoma
Gachechiladze, M. A., Škarda, J., Škanderová, D., Überall, I., Kolek, V., Smičková, P., Vojta, P., Vbrková, J., Hajdúch, M., Shani, I., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.06.025 · Cited by 14
Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer
Aiello, M. M., Solinas, C., Santoni, M., Battelli, N., Restuccia, N., Latteri, F., Paratore, S., Verderame, F., Albanese, G. V., Bruzzi, P., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01167 · Cited by 14
Proteomic profiling of soft tissue sarcomas with SWATH mass spectrometry
Milighetti, M., Krásný, L., Lee, A. T. J., Morani, G., Szecsei, C., Chen, Y., Guljar, N., McCarthy, F., Wilding, C. P., Arthur, A., et al. (2021) · Journal of Proteomics · doi:10.1016/j.jprot.2021.104236 · Cited by 15
De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
Ma, S.-C., Zhu, H., Wang, J., Zhang, Y.-P., Guo, X., Long, L.-L., Guo, Z.-Q., Wu, D., Dong, Z., & Bai, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.666145 · Cited by 14
Génotypage moléculaire dans les cancers réfractaires de la thyroïde en 2021 : quand, comment, et pourquoi ? Un travail du réseau TUTHYREF
de la Fouchardière, C., Wassermann, J., Calcagno, F., Bardet, S., Ghuzlan, A. A., Borget, I., Borson‐Chazot, F., Cao, C. D., Buffet, C., Zerdoud, S., et al. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2021.06.009 · Cited by 14
Current Treatment and Future Trends of Immunotherapy in Breast Cancer
Cescon, D. W., Elliott, M. J., & Wilson, B. E. (2022) · Current Cancer Drug Targets · doi:10.2174/1568009622666220317091723 · Cited by 14
Towards In Silico Prediction of the Immune-Checkpoint Blockade Response
Chen, K., Ye, H., Lu, X., Sun, B., & Liu, Q. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.10.002 · Cited by 14
Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature
Özdemir, B. C., Siefker-Radtke, A. O., Campbell, M. T., & Subudhi, S. K. (2017) · European Urology Focus · doi:10.1016/j.euf.2017.10.001 · Cited by 14
Metastatic Mixed Adenoneuroendocrine Carcinoma of the Colon with Response to Immunotherapy with Pembrolizumab: A Case Report
Stueger, A., Winder, T. L., Tinguely, M., Petrausch, U., & Helbling, D. (2019) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000279 · Cited by 14
Variable indoleamine 2,3‐dioxygenase expression in acral/mucosal melanoma and its possible link to immunotherapy
Iga, N., Otsuka, A., Hirata, M., Kataoka, T. R., Irie, H., Nakashima, C., Matsushita, S., Uchi, H., Yamamoto, Y., Funakoshi, T., et al. (2019) · Cancer Science · doi:10.1111/cas.14195 · Cited by 13
Diagnostic and prognostic value of preoperative systemic inflammatory markers in anaplastic thyroid cancer
Zhang, L., Luo, H., Wang, L., Liu, Y., Shu, R., Wu, Z., Wei, T., Gong, R., Li, Z., & Zhu, J. (2020) · Journal of Surgical Oncology · doi:10.1002/jso.26089 · Cited by 14
Liquid Biopsies to Evaluate Immunogenicity of Gynecological/Breast Tumors: On the Way to Blood-Based Biomarkers for Immunotherapies
Keup, C., Kimmig, R., & Kasimir‐Bauer, S. (2020) · Breast Care · doi:10.1159/000510509 · Cited by 15
Anti–PD-1 Monotherapy for Advanced NSCLC Patients with Older Age or Those with Poor Performance Status
Matsubara, T., Seto, T., Takamori, S., Fujishita, T., Toyozawa, R., Ito, K., Yamaguchi, M., & Okamoto, T. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s301500 · Cited by 14
It’s not ‘just a tube of blood’: principles of protocol development, sample collection, staffing and budget considerations for blood-based biomarkers in immunotherapy studies
Jiang, C. Y., Niu, Z., Green, M. D., Zhao, L., Raupp, S., Pannecouk, B., Brenner, D. E., Nagrath, S., & Ramnath, N. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003212 · Cited by 14
Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma
Zhang, H., Liu, Y., Wang, B., & Wang, C. (2022) · BMC Genomic Data · doi:10.1186/s12863-022-01076-4 · Cited by 14
Multi-omics identification of GPCR gene features in lung adenocarcinoma based on multiple machine learning combinations
Xie, Y., Pan, X., Wang, Z., Ma, H., Xu, W., Huang, H., Zhang, J., Wang, X., & Lian, C. (2024) · Journal of Cancer · doi:10.7150/jca.90990 · Cited by 13
In-depth proteomic analysis identifies key gene signatures predicting therapeutic efficacy of anti-PD-1/PD-L1 monotherapy in non-small cell lung cancer
Zhang, X., Gao, G., Zhang, Q., Zhao, S., Li, X., Cao, W., Luo, H., & Zhou, C. (2024) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-713 · Cited by 13
High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinoma
Klümper, N., Cox, A., Eckstein, M., Kuppe, C., Ritter, M., Brossart, P., Luetkens, J. A., Hölzel, M., Stein, J., & Saal, J. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114089 · Cited by 15
Mechanistic Insights into the Successful Development of Combination Therapy of Enfortumab Vedotin and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Urothelial Cancer
Taylor, C., Patterson, K. M., Friedman, D., Bacot, S. M., Feldman, G. M., & Wang, T. (2024) · Cancers · doi:10.3390/cancers16173071 · Cited by 17
Advancing precision cancer immunotherapy drug development, administration, and response prediction with AI-enabled Raman spectroscopy
Chadokiya, J., Chang, K., Sharma, S., Hu, J., Lill, J. R., Dionne, J. A., & Kirane, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1520860 · Cited by 13
Recent progress in immunotherapy for urological cancer
Obara, W., Kato, R., Kato, Y., Kanehira, M., & Takata, R. (2017) · International Journal of Urology · doi:10.1111/iju.13400 · Cited by 13
Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation
Jayant, K., Habib, N., Huang, K., Podda, M., Warwick, J., & Arasaradnam, R. P. (2020) · Vaccines · doi:10.3390/vaccines8020247 · Cited by 13
Mitoxantrone-Loaded Nanoparticles for Magnetically Controlled Tumor Therapy–Induction of Tumor Cell Death, Release of Danger Signals and Activation of Immune Cells
Ratschker, T., Egenberger, L., Alev, M., Zschiesche, L., Band, J., Schreiber, E., Frey, B., Derer, A., Alexiou, C., & Janko, C. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100923 · Cited by 13
Targeting the PD-1 Axis with Pembrolizumab for Recurrent or Metastatic Cancer of the Uterine Cervix: A Brief Update
Verhoeven, Y., Quatannens, D., Trinh, X. B., Wouters, A., Smits, E., Lardon, F., Waele, J. D., & van Dam, P. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041807 · Cited by 13
Immunomodulation by the Commensal Microbiome During Immune-Targeted Interventions: Focus on Cancer Immune Checkpoint Inhibitor Therapy and Vaccination
Reens, A. L., Cabral, D. J., Liang, X., Norton, J. E., Therien, A. G., Hazuda, D. J., & Swaminathan, G. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643255 · Cited by 14
TP53 Mutation Status and Biopsy Lesion Type Determine the Immunotherapeutic Stratification in Non-Small-Cell Lung Cancer
Lü, J., Zhong, R., Lou, Y., Hu, M., Yang, Z., Wang, Y., Chen, Y., Zou, B., Zhang, W., Wang, H., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.732125 · Cited by 14
A prognostic signature of pyroptosis-related lncRNAs verified in gastric cancer samples to predict the immunotherapy and chemotherapy drug sensitivity
Wang, Y., Chen, X., Jiang, F., Shen, Y., Fang, F., Li, Q., Yang, C., Dong, Y., & Shen, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.939439 · Cited by 13
Pyroptosis Predicts Immunotherapy Outcomes Across Multiple Cancer Types
Li, S., Chen, P., Cheng, B., Liu, Y., Zhang, X., Xu, Q., Huang, M., Dai, X., Huang, K., Zhang, L., et al. (2022) · Clinical Immunology · doi:10.1016/j.clim.2022.109163 · Cited by 13
Artificial intelligence and digital biomarker in precision pathology guiding immune therapy selection and precision oncology
Huss, R., Raffler, J., & Märkl, B. (2023) · Cancer Reports · doi:10.1002/cnr2.1796 · Cited by 13
Transcriptome evolution from breast epithelial cells to basal-like tumors
Santpere, G., Alcaraz-Sanabria, A. L., Corrales‐Sánchez, V., Pandiella, A., Győrffy, B., & Ocaña, A. (2017) · Oncotarget · doi:10.18632/oncotarget.23065 · Cited by 13
Alterations in ERBB2 and BRCA and microsatellite instability as new personalized treatment options in small bowel carcinoma
Quaas, A., Heydt, C., Waldschmidt, D., Alakus, H., Zander, T., Goeser, T., Kasper, P., Bruns, C. J., Brunn, A., Roth, W., et al. (2019) · BMC Gastroenterology · doi:10.1186/s12876-019-0942-z · Cited by 13
PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas
Pérottet, J., Goff, E. L., Legoupil, D., Quéré, G., Schick, U., Marcorelles, P., & Uguen, A. (2019) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000712 · Cited by 13
Treating non-responders: pitfalls and implications for cancer immunotherapy trial design
Xu, Z., Park, Y., Liu, K., & Zhu, B. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-0847-x · Cited by 14
Multi-Omics Perspective Reveals the Different Patterns of Tumor Immune Microenvironment Based on Programmed Death Ligand 1 (PD-L1) Expression and Predictor of Responses to Immune Checkpoint Blockade across Pan-Cancer
Huang, K., Hu, M., Chen, J., Wei, J., Qin, J., Lin, S., & Du, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22105158 · Cited by 13
Case Report: Dual Checkpoint Inhibition in Advanced Metastatic Osteosarcoma Results in Remission of All Tumor Manifestations—A Report of a Stunning Success in a 37-Year-Old Patient
Sterz, U., Grube, M., Herr, W., Menhart, K., Wendl, C., & Vogelhuber, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684733 · Cited by 12
BIPSE: A biomarker‐based phase I/II design for immunotherapy trials with progression‐free survival endpoint
Guo, B., & Zang, Y. (2021) · Statistics in Medicine · doi:10.1002/sim.9265 · Cited by 12
An Integrated Machine Learning Framework Identifies Prognostic Gene Pair Biomarkers Associated with Programmed Cell Death Modalities in Clear Cell Renal Cell Carcinoma
Chen, B., Zhou, M., Guo, L., Huang, H., Sun, X., Peng, Z., Wu, D., & Chen, W. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2903121 · Cited by 12
The heterogeneity of tumour-associated macrophages contributes to the clinical outcomes and indications for immune checkpoint blockade in colorectal cancer patients
Tang, J., Liang, M., Qin, F., Qin, Y., Wang, D., Huang, L., Cao, Y., Huang, Z., & Yin, Y. (2024) · Immunobiology · doi:10.1016/j.imbio.2024.152805 · Cited by 12
Comparative efficacy of immune checkpoint inhibitors combined with chemotherapy in patients with advanced driver-gene negative non-small cell lung cancer: A systematic review and network meta-analysis
Zhang, X., Wu, M., Chen, J., Zheng, K., Du, H., Li, B., Gu, Y., & Jiang, J. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30809 · Cited by 14
NLR stability predicts response to immune checkpoint inhibitors in advanced hepatocellular carcinoma
Du, J., & Huang, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-68048-9 · Cited by 12
Innovative design of bacterial outer membrane vesicles for vaccine development
Cheng, Q., Niu, G., He, Y., Zhu, Y., Kang, Y., Zhang, Z., & Ji, X. (2025) · Nano Today · doi:10.1016/j.nantod.2025.102650 · Cited by 12
Understanding the molecular bridges between the drugs and immune cell
Dash, U. C., Nayak, V., Navani, H. S., Samal, R. R., Agrawal, P., Singh, A. K., Majhi, S., Mogare, D., Duttaroy, A. K., & Jena, A. B. (2025) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2025.108805 · Cited by 13
A retrospective study of radiotherapy combined with immunotherapy for patients with baseline brain metastases from non-small cell lung cancer
Lu, R., Wang, Z., Tian, W., Shi, W., Chu, X., & Zhou, R. (2025) · Scientific Reports · doi:10.1038/s41598-025-91863-7 · Cited by 15
The Role of Eosinophils, Eosinophil-Related Cytokines and AI in Predicting Immunotherapy Efficacy in NSCLC
Omero, F., Speranza, D., Murdaca, G., Cavaleri, M., Marafioti, M., Cianci, V., Berretta, M., Casciaro, M., Gangemi, S., & Santarpía, M. (2025) · Biomolecules · doi:10.3390/biom15040491 · Cited by 13
To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade
Chung, C. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218786365 · Cited by 12
Hyperprogressive Disease In Cervical Small Cell Carcinoma Treated By Immune Checkpoint Inhibitor
Xu, Z., Chen, L., Zheng, L., Yang, Q., Chen, M., Wang, J., Zhu, G., Chen, Z., & Sun, J. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s213436 · Cited by 12
MIA-Prognosis: A Deep Learning Framework to Predict Therapy Response
Yang, J., Chen, J., Kuang, K., Lin, T., He, J., & Ni, B. (2020) · Lecture notes in computer science · doi:10.1007/978-3-030-59713-9_21 · Cited by 12
MGA Mutation as a Novel Biomarker for Immune Checkpoint Therapies in Non-Squamous Non-Small Cell Lung Cancer
Sun, L., Li, M., Deng, L., Niu, Y., Tang, Y., Wang, Y., & Guo, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.625593 · Cited by 13
The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
Ba, H., Liu, L., Peng, Q., Chen, J., & Zhu, Y. (2021) · BMC Cancer · doi:10.1186/s12885-021-08924-z · Cited by 12
A Comprehensive Prognostic Analysis of POLD1 in Hepatocellular Carcinoma
Tang, H. J., You, T., Sun, Z., & Bai, C. (2022) · BMC Cancer · doi:10.1186/s12885-022-09284-y · Cited by 12
Genomic Variations and Immune-Related Features of TMB, PD-L1 Expression and CD8+ T Cell Infiltration in Chinese Pulmonary Sarcomatoid Carcinoma
Zhang, C., Li, Z., Zhang, Y., Zhao, C., Wang, H., Lin, J., Liu, C., Wang, X., & Wang, H. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s357659 · Cited by 12
A risk scoring system based on tumor microenvironment cells to predict prognosis and immune activity in triple-negative breast cancer
Yang, A., Wu, M., Ni, M., Zhang, L., Li, M., Wei, P., Yang, Y., Xiao, W., & An, X. (2022) · Breast Cancer · doi:10.1007/s12282-021-01326-w · Cited by 11
Identification of a seven-gene signature predicting clinical outcome of liver cancer based on tumor mutational burden
Cui, Y., & Jiang, N. (2022) · Human Cell · doi:10.1007/s13577-022-00708-2 · Cited by 12

Authors: Gibney, G. T., Weiner, L. M., & Atkins, M. B.
Affiliations: Georgetown University Medical Center (US)
Corresponding author: Gibney, Geoffrey T
ORCID: Gibney, Geoffrey T
Weiner, Louis M
Atkins, Michael B
Venue: The Lancet Oncology
Publisher: Elsevier BV
Published: 2016-12
Volume: 17
Issue: 12
Pages: e542-e551
ISSN: 1470-2045 (ISSN-L)
DOI: 10.1016/s1470-2045(16)30406-5
PMC: PMC5702534
OpenAlex: W2559382297
Cited by: 1,635
References: 76
Citations by year: 2026: 62 · 2025: 111 · 2024: 161 · 2023: 222 · 2022: 238 · 2021: 229 · 2020: 248 · 2019: 171 · 2018: 109 · 2017: 83
FWCI: 11.76
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
Locations: The Lancet Oncology (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Cancer Institute (R01CA050633, P30CA051008)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
Keywords: predictive biomarkers, immune checkpoint inhibitors, PD-1, PD-L1 expression, tumor-infiltrating lymphocytes, tumor mutational burden, immune-related gene signature, multiplex immunohistochemistry, immune-related adverse events, patient selection, melanoma
MeSH terms: Humans, Immunohistochemistry, Immunotherapy, Neoplasms, Biomarkers, Lymphocytes, Tumor-Infiltrating, Tumor Microenvironment, Cell Cycle Checkpoints, B7-H1 Antigen

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Predictive biomarkers for checkpoint inhibitor-based immunotherapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks